A multicenter cohort study confirmed the expressions of soluble serum LOX-1 prominently elevated in CAD patients treated with primary percutaneous coronary intervention (PCI), they also noticed higher serum sLOX-1concentrations were directly associated with negative impact on cardiovascular and cerebrovascular events (MACCEs), perhaps sLOX-1 considered as a diagnostic and prognostic biomarker22. This evidence concerns the gene OLR1 and coronary artery disorder.